ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2689

Comparison of the 2016 ACR/EULAR and the 2002 AECG Classification Criteria in a Cohort of Patients with Suspected Primary SjöGren’s Syndrome

Divi Cornec1, Maëlle Le Goff2, Sandrine Jousse-Joulin3, Dewi Guellec4, Sebastian Costa5, Thierry Marhadour6, Jacques-Olivier Pers7, Alain Saraux8 and Valerie Devauchelle-Pensec9, 1Department of rheumatology, Brest Occidentale University, Brest, France, 2CHRU Brest, Brest, France, 3Rheumatology, CHu La cavle Blanche, Brest, France, 4Rheumatology Department, CHU de la Cavale Blanche, Brest, France, 5anatomopathological department, Brest university hospital, Brest, France, 6Rheumatology, CHU La Cavale Blanche, Brest, France, 7INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, 8Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 9Rheumatology Department, Brest University Hospital, Brest, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Sjogren's syndrome and classification criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: New consensual classification criteria for primary Sjögren’s syndrome (pSS) have been recently developed, validated, and submitted to ACR and EULAR committees. They differ substantially from previously used AECG criteria in that they consider systemic involvement (defined as ESSDAI score ≥1) as well as sicca symptoms as entry criteria before applying a weighted score. Evaluation of the concordance and differences between the two sets of criteria in independent patient populations is mandatory to establish how future clinical studies using the new criteria will be comparable to previously published studies.

Methods: This cross-sectional study was conducted in the monocentric Brittany cohort (DIApSS cohort) of patients with suspected pSS (sicca symptoms, parotidomegaly or extraglandular manifestations suggestive of pSS). All patients had standardized clinical examination, basic biology, immunological tests and minor labial salivary gland biopsy. Major salivary gland ultrasonography (SGUS) in mode B was performed in all patients by the same experienced operator, who was blinded to the diagnosis. Agreement between the two sets of criteria was assessed using Cohen’s κ coefficient and the characteristics of discordant patients were detailed.

Results: 163 patients were prospectively included between 2006 and 2016. Mean age was 56±14 years, female percentage 94%, and mean duration of the symptoms 6.8±7.9 years. More patients fulfilled ACR/EULAR criteria (n=93, 57%) than AECG criteria (n=83, 51%). 80 patients (49%) fulfilled both criteria, 13 (8%) fulfilled ACR/EULAR only, 3 (2%) AECG only and 67 (41%) none of the criteria. Concordance between both criteria was good (kappa=0.8, agreement 90%). Compared to patients fulfilling both criteria, patients fulfilling ACR/EULAR but not AECG criteria (n = 13) had similar age (56 vs 57 years), shorter disease duration (mean 5.9±8.5 vs 8.2±8.9 years), less frequent sicca symptoms (eye dryness 50% vs 96%, mouth dryness 64% vs 96%) and salivary gland swelling (14% vs 28%). They had characteristic features of pSS, with frequent systemic involvement at diagnosis (88%), positive salivary gland biopsy (86%), abnormal SGUS (67%) and presence of anti-SSA/SSB autoantibodies (57%). Among patients negative for the two sets of criteria, 10% had an abnormal SGUS and received a clinical diagnosis of pSS based on physician opinion.

Conclusion: Agreement between AECG criteria and new ACR/EULAR criteria is good suggesting that they select quite similar patients. ACR/EULAR criteria display a slightly higher sensitivity and are able to detect more patients with early disease and systemic involvement. As previously demonstrated for AECG criteria, SGUS inclusion into ACR/EULAR criteria may further enhance their sensitivity.


Disclosure: D. Cornec, None; M. Le Goff, None; S. Jousse-Joulin, None; D. Guellec, None; S. Costa, None; T. Marhadour, None; J. O. Pers, None; A. Saraux, None; V. Devauchelle-Pensec, None.

To cite this abstract in AMA style:

Cornec D, Le Goff M, Jousse-Joulin S, Guellec D, Costa S, Marhadour T, Pers JO, Saraux A, Devauchelle-Pensec V. Comparison of the 2016 ACR/EULAR and the 2002 AECG Classification Criteria in a Cohort of Patients with Suspected Primary SjöGren’s Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparison-of-the-2016-acreular-and-the-2002-aecg-classification-criteria-in-a-cohort-of-patients-with-suspected-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-2016-acreular-and-the-2002-aecg-classification-criteria-in-a-cohort-of-patients-with-suspected-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology